SCHEMBL2298384

SCHEMBL2298384

C(#CC1CC[N]CC1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.42
FFAR1 O14842 3/20 0.40
GRM5 P41594 2/20 0.40
CYP1A2 P05177 2/20 0.40
FFAR4 Q5NUL3 2/20 0.38
PTGES O14684 1/20 0.36
NOS2 P35228 1/20 0.35
HAO1 Q9UJM8 5/20 0.35
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
CASP3 P42574 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
KCNH2 Q12809 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18626138 0.85 APP (0.52) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL2565461 0.85 APP (0.52) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL11232546 0.81 FFAR1 (0.53) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL15266861 0.81 FFAR1 (0.49) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL11225320 0.79 CYP1A2 (0.55) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL8752132 0.79 CYP1A2 (0.55) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL22622902 0.76 GRM5 (0.44) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL28789381 0.76 HAO1 (0.45) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL1200030 0.76 SIGMAR1 (0.45) APPFFAR1GRM5CYP1A2FFAR4
SCHEMBL20613702 0.74 FFAR1 (0.46) APPFFAR1GRM5CYP1A2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I APP 3147/4885FFAR1 1932/4885GRM5 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.